Abstract：Objective: To investigate the correlation between BPE (Background parenchymal enhancement) and molecular subtypes and common prognostic markers of breast cancer. Methods: A retrospective analysis was made on the clinical data of 60 female patients examined by breast MRI in our hospital from January 2017 to April 2018. All patients were examined by GE MR750 3.0T superconducting magnetic resonance scanning system in the United States, and had complete dynamic enhanced image results. All patients received immunohistochemical tests, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) and Ki-67 index. Pathological and molecular subtype results were analyzed to investigate the correlation between BPE, FGT and molecular subtypes and prognostic markers. Results: 60 cases of breast cancer were classified as invasive ductal carcinoma in 54 cases, intraductal papillary carcinoma in 2 cases and ductal carcinoma in situ in 4 cases. Molecular subtypes: 19 cases of Luminal A, 26 cases of Luminal B, 12 cases of HER-2 overexpression and 3 cases of TNBC. The distribution of BPE and FGT: BPE was BPE 1 (14,23.3%), BPE 2 (27,45%), BPE 3 (12,20%) and BPE 4 (7,11.7%). The distribution of FGT was FGT 1 (2,3.4%), FGT 2 (15,25%) and FGT 3 (23,38.3%) FGT 4 (20,33.3%). The average age of patients with high BPE and FGT was lower than that of patients with low BPE and FGT, and the difference was statistically significant (t value was 3.8, 2.5, P value was 0.008 and 0.01, respectively). The average Ki-67 index was not significantly correlated with BPE and FGT in high and low groups (t value was 6.1, 5.8, P value was 0.45 and 0.43, respectively). The results of correlation analysis showed that there was no correlation between high BPE and FGT in Luminal B, HER-2 overexpression breast cancer and TNBC compared with Luminal A breast cancer (P > 0.05). In the comparison of menstrual status, BPE and FGT in premenopausal patients were higher than those in postmenopausal patients (2 values were 20.5, 18.23, P values were 0.007 and 0.004 respectively). In other prognostic markers, high BPE had no significant correlation with lymph node status, histological grade and Ki-67 expression (P > 0.05). Conclusion:Some patients with poor prognosis, such as HER-2 overexpression breast cancer or TNBC, have no increased risk of BPE. There was no significant correlation between BPE elevation and negative prognostic markers such as positive axillary lymph node, high expression of Ki-67 index and high histological grade.
朱娟, 朱宜春. MRI乳腺背景实质强化与乳腺癌分子亚型的相关性研究[J]. 河北医学, 2019, 25(9): 1571-1576.
ZHU Juan, ZHU Yichun. Study on the Correlation between Background Enhancement of Breast and Molecular Subtypes of Breast Cancer on Magnetic Resonance Imaging. HeBei Med, 2019, 25(9): 1571-1576.
[1] Dong JM,Wang HX,Zhong XF,et al.Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response[J].Medicine (Baltimore),2018,97(43):e12965. [2] 王敏红,周运锋,周理想,等.乳腺MRI背景实质分型及强化对乳腺癌的辅助诊断价值[J].临床放射学杂志,2018,37(1):49~53. [3] Iacconi C,Galman L,Zheng J,et al.Multicentric Cancer Detected at Breast MR Imaging and Not at Mammography: Important or Not[J] Radiology,2016,279(2):378~384. [4] Kerlikowske K,Ma L,Scott CG,et al.Combining quantitative and qualitative breast density measures to assess breast cancer risk[J].Breast Cancer Res,2017,19(1):97. [5] King V,Brooks JD,Bernstein JL,et al.Background parenchymal enhancement at breast MR imaging and breast cancer risk[J].Radiology,2011,260(1):50~60. [6] 王海彬,魏秋良,崔振华,等.不同分子亚型乳腺癌患者动态增强MRI的定量参数变化[J].临床与病理杂志,2018,38(11):180~187. [7] Lin NU,Vanderplas A,Hughes ME,et al.Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network[J].Cancer,2012,118(22):5463–5472. [8] 孟欣,任瑞美,MENGXin,等.动态增强磁共振与乳腺癌分子亚型血管生成的相关性研究[J].中华肿瘤防治杂志,2016,23(12):806~811,815.
2019, Vol. 25 
冀公网安备13080202000677号